Andrea Favre-Bulle
5PUBLICATIONS
14CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Feb 18, 2026
Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.Muloongo Simuzingili, Andrea Favre-Bulle, Thomas Mutschler
|Jul 14, 2025
Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis.Nikolaos Kotsopoulos, Mark P Connolly, Selim Nur
|Jun 21, 2024
Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework.Cillian Copeland, Nikos Kotsopoulos, Andrea Favre-Bulle
|Nov 24, 2023
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.Andrea Favre-Bulle, Min Huang, Amin Haiderali
|Feb 07, 2023
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.Andrea Favre-Bulle, Goran Bencina, Shujing Zhang
Pageof 1
Frequent Collaborators
2 joint publications
Goran Bencina
2 joint publications
Arjun Bhadhuri
2 joint publications
Nikos Kotsopoulos
1 joint publications
Shujing Zhang
1 joint publications
Ruixuan Jiang
1 joint publications
Daniel Andritschke
1 joint publications
Min Huang
1 joint publications
Cillian Copeland
1 joint publications
Demet Sönmez
1 joint publications
Stina Salomonsson
